165 related articles for article (PubMed ID: 36789991)
1. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
Tomaszewska-Kiecana M; Ullmann M; Petit-Frere C; Monnet J; Dagres C; Illes A
Expert Rev Clin Immunol; 2023 Apr; 19(4):439-446. PubMed ID: 36715299
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
6. Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector.
Fettner S; Mela C; Wildenhahn F; Tavanti M; Wells C; Douglass W; Mallalieu NL
Expert Opin Drug Deliv; 2019 May; 16(5):551-561. PubMed ID: 31043095
[TBL] [Abstract][Full Text] [Related]
7. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
Bush J; Kawakami K; Muniz R
BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
[TBL] [Abstract][Full Text] [Related]
8. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers.
Zhang W; Tyrrell H; Ding HT; Pulley J; Boruvka A; Erickson R; Abouhossein M; Ravanello R; Tang MT
Adv Ther; 2021 May; 38(5):2418-2434. PubMed ID: 33778929
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
Shin D; Lee Y; Jeong D; Ellis-Pegler R
Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Sangana R; Xu Y; Shah B; Tian X; Zack J; Shakeri-Nejad K; Kalluri S; Jones I; Ligueros-Saylan M; Taylor AF; Jain DK; Scosyrev E; Uddin A; Laurent N; Paganoni P
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):611-620. PubMed ID: 38389387
[TBL] [Abstract][Full Text] [Related]
11. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
[TBL] [Abstract][Full Text] [Related]
12. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection.
Lon HK; Cheng L; Nudurupati S; Loebbert R; Duan R; Kalabic J; Pang Y
Clin Ther; 2021 Mar; 43(3):629-636. PubMed ID: 33549311
[TBL] [Abstract][Full Text] [Related]
14. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.
Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J
Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe.
Cohen YZ; Zhang X; Xia B; Kosloski MP; Kamal MA; Davis JD; Kanamaluru V; Xu C
Clin Pharmacol Drug Dev; 2022 May; 11(5):675-681. PubMed ID: 35278283
[TBL] [Abstract][Full Text] [Related]
16. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects.
Shin D; Kim Y; Go A; Velinova M
Drug Des Devel Ther; 2020; 14():43-50. PubMed ID: 32021090
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
19. A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
Cherniakov I; Cohen-Barak O; Tiver R; Gillespie M; Kessler Y; Gutierrez M; Rasamoelisolo M; Li S; Shen H; Hallak H; Loupe PS; Smith M; Rabinovich-Guilatt L; Spiegelstein O
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1018-1027. PubMed ID: 33411992
[TBL] [Abstract][Full Text] [Related]
20. Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO
Lacombe O; Pletan Y; Grouin JM; Brennan A; Giré O
Neurol Ther; 2024 May; ():. PubMed ID: 38806873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
